Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models.

Parks A, Charest-Morin X, Boivin-Welch M, Bouthillier J, Marceau F.

PeerJ. 2015 Oct 6;3:e1314. doi: 10.7717/peerj.1314. eCollection 2015.

2.

Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.

Charest-Morin X, Raghavan A, Charles ML, Kolodka T, Bouthillier J, Jean M, Robbins MS, Marceau F.

Pharmacol Res Perspect. 2015 Mar;3(2):e00119. doi: 10.1002/prp2.119. Epub 2015 Feb 10.

3.

Pharmacological evidence of bradykinin regeneration from extended sequences that behave as peptidase-activated B2 receptor agonists.

Charest-Morin X, Roy C, Fortin EJ, Bouthillier J, Marceau F.

Front Pharmacol. 2014 Mar 7;5:32. doi: 10.3389/fphar.2014.00032. eCollection 2014.

4.

Assessment of cation trapping by cellular acidic compartments.

Marceau F, Roy C, Bouthillier J.

Methods Enzymol. 2014;534:119-31. doi: 10.1016/B978-0-12-397926-1.00007-X.

PMID:
24359951
5.

Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs.

Marceau F, Bawolak MT, Lodge R, Bouthillier J, Gagné-Henley A, Gaudreault RC, Morissette G.

Toxicol Appl Pharmacol. 2012 Feb 15;259(1):1-12. doi: 10.1016/j.taap.2011.12.004. Epub 2011 Dec 13. Review.

6.

Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue.

Gera L, Roy C, Bawolak MT, Bouthillier J, Adam A, Marceau F.

Pharmacol Res. 2011 Nov;64(5):528-34. doi: 10.1016/j.phrs.2011.08.001. Epub 2011 Aug 11.

7.

Vascular smooth muscle contractility assays for inflammatory and immunological mediators.

Marceau F, deBlois D, Petitclerc E, Levesque L, Drapeau G, Audet R, Godin D, Larrivée JF, Houle S, Sabourin T, Fortin JP, Morissette G, Gera L, Bawolak MT, Koumbadinga GA, Bouthillier J.

Int Immunopharmacol. 2010 Nov;10(11):1344-53. doi: 10.1016/j.intimp.2010.08.016. Epub 2010 Sep 8. Review.

8.

Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors.

Bawolak MT, Fortin S, Bouthillier J, Adam A, Gera L, C-Gaudreault R, Marceau F.

Br J Pharmacol. 2009 Nov;158(5):1375-86. doi: 10.1111/j.1476-5381.2009.00409.x. Epub 2009 Sep 28.

9.

Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: a model for the distribution of lipophilic cationic drugs to autophagic vacuoles.

Marceau F, Bawolak MT, Bouthillier J, Morissette G.

Drug Metab Dispos. 2009 Dec;37(12):2271-4. doi: 10.1124/dmd.109.028480. Epub 2009 Sep 22.

10.

Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle.

Koumbadinga GA, Petitclerc E, Bouthillier J, Adam A, Marceau F.

Eur J Pharmacol. 2009 Mar 15;606(1-3):233-9. doi: 10.1016/j.ejphar.2008.12.058. Epub 2009 Jan 21.

PMID:
19374866
11.

Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression.

Bawolak MT, Gera L, Morissette G, Bouthillier J, Stewart JM, Gobeil LA, Lodge R, Adam A, Marceau F.

J Pharmacol Exp Ther. 2009 Apr;329(1):159-68. doi: 10.1124/jpet.108.149724. Epub 2009 Jan 9.

12.

A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging.

Bawolak MT, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F.

Peptides. 2008 Sep;29(9):1626-30. doi: 10.1016/j.peptides.2008.05.007. Epub 2008 May 17.

PMID:
18565624
13.

Receptor-independent, vacuolar ATPase-mediated cellular uptake of histamine receptor-1 ligands: possible origin of pharmacological distortions and side effects.

Morissette G, Lodge R, Bouthillier J, Marceau F.

Toxicol Appl Pharmacol. 2008 Jun 15;229(3):320-31. doi: 10.1016/j.taap.2008.01.028. Epub 2008 Feb 7.

PMID:
18328520
14.

Trapping of adrenergic decongestant drugs into cellular endomembrane compartments: toxicological and pharmacological consequences.

Morissette G, Bouthillier J, Marceau F.

Int Immunopharmacol. 2007 Dec 20;7(14):1869-79. Epub 2007 Jul 27.

PMID:
18039524
15.
16.

Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta.

Fortin JP, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F.

J Pharmacol Exp Ther. 2005 Sep;314(3):1169-76. Epub 2005 May 26.

17.

A novel nonpeptide antagonist of the kinin B1 receptor: effects at the rabbit receptor.

Morissette G, Fortin JP, Otis S, Bouthillier J, Marceau F.

J Pharmacol Exp Ther. 2004 Dec;311(3):1121-30. Epub 2004 Jul 26.

18.

Characterization of a fluorescent conjugate of the rabbit angiotensin AT(1) receptor.

Fortin JP, Bouthillier J, Bastien L, Bachvarov DR, Marceau F.

Br J Pharmacol. 2003 Apr;138(8):1495-504.

19.

High agonist-independent clearance of rabbit kinin B1 receptors in cultured cells.

Fortin JP, Bouthillier J, Marceau F.

Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1647-54. Epub 2003 Jan 9.

20.

Contractile effect of anaphylatoxin C5a and of a mimetic peptide on the human umbilical artery: further evidence for leukocyte-dependent vasomotion.

Fortin JP, Bouthillier J, St-Pierre SA, Marceau F.

J Cardiovasc Pharmacol. 2002 Dec;40(6):815-21.

PMID:
12451314

Supplemental Content

Loading ...
Support Center